181 related articles for article (PubMed ID: 12943520)
1. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women.
Yavuz D; Deyneli O; Akpinar I; Yildiz E; Gözü H; Sezgin O; Haklar G; Akalin S
Eur J Endocrinol; 2003 Sep; 149(3):187-93. PubMed ID: 12943520
[TBL] [Abstract][Full Text] [Related]
2. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.
Jiang XB; Li CL; He DS; Mao ZG; Liu DH; Fan X; Hu B; Zhu YH; Wang HJ
Pituitary; 2014 Jun; 17(3):232-9. PubMed ID: 23756783
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
5. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
7. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
[TBL] [Abstract][Full Text] [Related]
8. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
9. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
10. Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
J Clin Pharmacol; 2019 Jan; 59(1):83-89. PubMed ID: 30129670
[TBL] [Abstract][Full Text] [Related]
11. Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment.
Tørring O; Isberg B; Sjöberg HE; Bucht E; Hulting AL
Acta Endocrinol (Copenh); 1993 May; 128(5):423-7. PubMed ID: 8317189
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharmacol; 2023 Aug; 63(8):886-894. PubMed ID: 37042432
[TBL] [Abstract][Full Text] [Related]
14. Insulin sensitivity and hyperprolactinemia.
Tuzcu A; Bahceci M; Dursun M; Turgut C; Bahceci S
J Endocrinol Invest; 2003 Apr; 26(4):341-6. PubMed ID: 12841542
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients.
Tezcan H; Yavuz D; Toprak A; Akpinar I; Koç M; Deyneli O; Akalin S
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):119-23. PubMed ID: 12806595
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.
Tuzcu A; Yalaki S; Arikan S; Gokalp D; Bahcec M; Tuzcu S
Pituitary; 2009; 12(4):330-4. PubMed ID: 19408128
[TBL] [Abstract][Full Text] [Related]
17. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma.
Seki K; Nagata I
Gynecol Obstet Invest; 1991; 31(4):222-5. PubMed ID: 1885092
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of 246 hyperprolactinemic patients.
Touraine P; Plu-Bureau G; Beji C; Mauvais-Jarvis P; Kuttenn F
Acta Obstet Gynecol Scand; 2001 Feb; 80(2):162-8. PubMed ID: 11167213
[TBL] [Abstract][Full Text] [Related]
19. The effect of prolactin and bromocriptine on human peripheral immune status.
Kadioglu P; Açbay O; Demir G; Gazioglu N; Gundogdu S
J Endocrinol Invest; 2001 Mar; 24(3):147-51. PubMed ID: 11314742
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Krysiak R; Basiak M; Machnik G; Szkróbka W; Okopień B
Nutrients; 2023 May; 15(10):. PubMed ID: 37242186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
